Abstract:Glycoprotein, which has glycan branches on its protein surface, is one of major forms of proteins existing in human body [1]. Its sugar composition and branched structure are known to be very specific to differentiation stages or pathologic changes of cell [1]. Therefore, as a glycoprotein-based biomarkers (glyco-biomarkers), it has been already used as laboratory tests like hemoglobin A1c for blood glucose monitoring or carbohydrate-deficient transferrin for chronic alcohol consumption [1, 2]. A new glycobiomarker named Mac-2 binding protein glycosylation isomer (M2BPGi, Wisteria floribunda agglutinin-positive Mac-2 binding protein) is emerging as a serum marker for liver fibrosis. Liver fibrosis results from sustained hepatic injury and is characterized by excessive accumulation of fibrotic tissue and distortion of the normal hepatic architecture [3, 4]. Fibrotic change is originally considered irreversible; however, liver fibrosis regression or restoration of the functional capacity can be achieved by controlling hepatic damage with some antiviral agents [3, 4]. Therefore, the extent and degree of liver fibrosis can provide important prognostic information on patient outcomes [4]. For assessing liver fibrosis, conventional liver biopsy still remains the gold standard method [5]. However, due to its invasiveness and discomfort for patients, liver biopsy cannot be performed frequently [4]. In addition, various non-invasive scoring systems using elastographic methods or serum markers have been proposed as surrogate tools [3]. Among serum biomarkers for liver fibrosis, M2BPGi, has been recently introduced in laboratories as a commercially available form. Many clinical and laboratory data have been accumulated to show that M2BPGi can be a useful serum marker for evaluating liver fibrosis in various chronic liver diseases such as chronic hepatitis C virus infection, autoimmune hepatitis, primary biliary cholangitis, and non-alcoholic fatty liver disease [6]. In this issue, we introduce two respective original studies investigating its diagnostic availability for assessing liver fibrosis. The authors reported interesting results of comparison between M2BPGi and other serologic markers, transient elastography, and various scoring systems [3, 7]. M2BPGi is on the status of surrogate marker, which cannot fully substitute for liver biopsy; however, based on continuous efforts for finding new blood markers and promoting their diagnostic efficacy, we carefully hope that the new era for non-invasive assessment of liver fibrosis towards liquid biopsy might be realized in the field of liver diseases in the near future [4].

Serum Wisteria Floribunda Agglutinin‐positive Mac‐2‐binding Protein Evaluates Liver Function and Predicts Prognosis in Liver Cirrhosis

Serum WFA+‐M2BP Levels for Evaluation of Early Stages of Liver Fibrosis in Patients with Chronic Hepatitis B Virus Infection

Prognostic Role of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Level in Early Stage Hepatocellular Carcinoma

Comparison of the diagnostic performance of magnetic resonance elastography and Wisteria foribunda agglutinin-positive Mac-2-binding protein in the determination of advanced liver fibrosis stages in patients with chronic liver disease

Mac-2 Binding Protein Glycosylation Isomer: Emerging Non-Invasive Serum Marker for Liver Fibrosis

Hepatic stellate cells secreting WFA+ -M2BP: Its role in biological interactions with Kupffer cells

Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases

Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis

Value of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Review of its Serum Biomarker Role

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

Modelling hepatitis C infection and pathogenicity with the human immune system and liver (HIL) mouse model

Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients

Serum Proteomic MRM Identify Peptide Ions of Transferrin As New Fibrosis Markers in Chronic Hepatitis B.

Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis.

Prognostic Utility of Novel Biomarkers in Acute-on-chronic Liver Failure (ACLF) Associated with Hepatitis B: A Multicenter Prospective Study.

On‐treatment Changes of Serum Wisteria Floribunda Agglutinin‐positive Mac‐2 Binding Protein Are Associated with the Regression of Liver Fibrosis in Chronic Hepatitis B Patients on Interferon Α Add‐on Therapy

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

Serum MRM assay for stage-related protein biomarkers on HBV infected liver fibrosis patients

The HCV serum proteome: a search for fibrosis protein markers

Serum Metabolite Profiles Are Associated with the Presence of Advanced Liver Fibrosis in Chinese Patients with Chronic Hepatitis B Viral Infection

Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels